| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_563c667842ce95888b891b6c7b99dca6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2019-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_974bfbce4213444803848b65d89a300d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_616e19f45b603f3fc7f4c4f1a8aef6e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9b635830af065b386b22d2e045b7db3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_461429c64c5a4cd9d08786f32675050e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e2b1ef224b857989cfd8ad15ad62c5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a16074441a507de69d27d2ac700896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_673989522a5bc4103035f46d16f98168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c20eeb710f38f5813f5c05581ac63034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db7790439d68ffe44ec1a58e097eb992
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0965a816cd5380eb4a023353f7ca6bd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f10c41e813e2417eaba74504d817d74 |
| publicationDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020038498-A1 |
| titleOfInvention |
Pharmaceutical combination comprising epidermal growth factor and secretagogue peptide ghrp6 for the restoration of brain damage |
| abstract |
The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the secretagogue peptide GHRP6, useful for the restoration of brain damage, by stimulating neuronal specialization and differentiation mechanisms in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The therapeutic efficacy of the pharmaceutical combination is independent of whether the pharmacological intervention occurs in the first hours after brain damage, which broadens the therapeutic window. |
| priorityDate |
2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |